XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

XTX Topco Ltd acquired a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 15,196 shares of the biopharmaceutical company’s stock, valued at approximately $129,000.

Several other institutional investors also recently modified their holdings of the company. Kennedy Capital Management LLC increased its stake in Theravance Biopharma by 3.7% in the first quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,532 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Theravance Biopharma by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,824 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in shares of Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 4,990 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Theravance Biopharma by 11.7% during the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 6,026 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 1.9 %

TBPH opened at $8.21 on Wednesday. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.71. The stock has a market capitalization of $401.63 million, a PE ratio of -9.55 and a beta of 0.24. The firm has a 50-day moving average price of $8.44 and a two-hundred day moving average price of $8.83.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The company had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. During the same period in the prior year, the business earned ($0.28) EPS. On average, research analysts predict that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha purchased 999,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli Samaha acquired 999,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The disclosure for this purchase can be found here. 6.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TBPH has been the topic of a number of analyst reports. TD Cowen lowered their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.